Table 2.
Outcome of body composition components, handgrip strength, health-related quality of life and biochemical measurements
| Months | All patients | Group N | Group B | Group C | p-value | |
|---|---|---|---|---|---|---|
| Body mass, kg (SD) | a0-6 | −2.1 (3.5) | −2.0 (3.5) | −3.0 (3.8) | −1.2 (3.2) | 0.29 |
| b0-12 | −1.6 (4.0) | −1.8 (3.0) | −2.2 (4.6) | −0.9 (4.1) | 0.69 | |
| FFM, kg (SD) | a0-6 | −1.5 (2.5) | −2.4 (2.0) | −1.3 (3.2) | −1.0 (1.9) | 0.09 |
| b0-12 | −1.6 (2.7) | −2.2 (2.5) | −1.4 (3.2) | −1.3 (2.2) | 0.41 | |
| FM, Kg (SD) | a0-6 | −0.6 (2.9) | +0.4 (2.3) | −1.7 (3.6) | −0.2 (2.1) | 0.06 |
| b0-12 | −0.2 (3.4) | +0.4 (2.1) | −0.7 (4.4) | −0.1 (3.0) | 0.64 | |
| aLM, kg (SD) | a0-6 | −0.1 (1.6) | −0.7 (1.4) | +0.3 (1.9) | +0.02 (1.4) | 0.06 |
| b0-6 | −0.2 (1.6) | −0.4 (1.5) | −0.02 (2.0) | −0.2 (1.4) | 0.40 | |
| FFMI, kg/m2 (SD) | a0-6 | −0.6 (0.9) | −0.9 (0.7) | −0.4 (1.2) | −0.4 (0.8) | 0.08 |
| b0-12 | −0.6 (1.0) | −0.8 (0.9) | −0.5 (1.2) | −0.5 (0.8) | 0.31 | |
| FMI | a0-6 | −0.2 (1.1) | 0.1 (0.8) | −0.6 (1.4) | −0.1 (0.8) | 0.06 |
| kg/m2 (SD) | b0-12 | −0.1 (1.2) | 0.1 (0.8) | −0.3 (1.6) | −0.1 (1.1) | 0.62 |
| aLMI | a0-6 | 0.0 (0.6) | −0.2 (0.5) | +0.1 (0.7) | 0.0 (0.6) | 0.03 |
| kg/m2 (SD) | b0-12 | −0.1 (0.6) | −0.2 (0.5) | 0.0 (0.7) | −0.1 (0.5) | 0.30 |
| HGS, kg (SD) | c0-6 | 1.4 (4.8) | 2.6 (4.7) | −0.3 (4.0) | 2.2 (5.4) | 0.09 |
| d0-12 | −1.0 (5.8) | −0.06 (6.6) | −3.0 (6.1) | −0.2 (5.7) | 0.22 | |
| EQ-5Dindex (SD) | c6 | 0.77 (0.23) | 0.75 (0.32) | 0.76 (0.20) | 0.78 (0.19) | 0.57 |
| d12 | 0.74 (0.23) | 0.76 (0.22) | 0.70 (0.25) | 0.75 (0.24) | 0.60 | |
| S-IGF-I,μg/L (range) | 6 | 124 (31–280) | 124 (39–265) | 135 (45–280) | 117 (31–236) | 0.39 |
| 12 | 119 (45–310) | 111 (45–205) | 137 (68–310) | 129 (66–202) | 0.35 | |
| S-IGF-I, SD score | 6 | 0.4 | 0.4 | 0.6 | 0.1 | 0.42 |
| 12 | 0.2 | 0.1 | 0.7 | 0.4 | 0.58 | |
| P-Alb, g/L (range) | 6 | 38 (24–47) | 37 (28–46) | 38 (24–42) | 39 (33–47) | 0.48 |
| 12 | 38 (28–46) | 40 (29–46) | 37 (34–45) | 39 (33–45) | 0.31 | |
| B-Hgb, g/L (range) | 6 | 134 (107–171) | 136 (110–171) | 134 (113–160) | 132 (107–154) | 0.89 |
| 12 | 136 (109–162) | 136 (109–162) | 134 (115–153) | 136 (115–151) | 0.84 | |
| S-CRP, mg/L (range) | 6 | 0 (0–48) | 4 (0–32) | 0 (0–48) | 0 (0–17) | 0.15 |
| 12 | 1 (0–21) | 2 (0–21) | 1 (0–8) | 1 (0–6) | 0.24 | |
| P-Creatinine, μmol/L (range) | 6 | 71 (41–173) | 67 (41–123) | 76 (55–117) | 72 (50–173) | 0.38 |
| 12 | 73 (41–173) | 67 (43–127) | 80 (57–128) | 71 (49–118) | 0.19 |
Group N = protein and energy supplementation for 6 months, and risedronate, vitamin D and calcium for 12 months, B = risedronate, vitamin D and calcium for 12 months, C = vitamin D and calcium for 12 months. Body mass (lean mass, fat mass and bone mineral content); FFM, fat free mass; FM, fat mass; aLM, appendicular lean mass; FFMI, fat free mass index; FMI, fat mass index; HGS, handgrip strength; EQ-5Dindex, the 5-Dimentional Scale of the HRQoL; S-IGF-I, serum-insulin growth factor-I; P-Alb, plasma-Albumin; B-Hgb, blood-Hemoglobin; S-CRP, serum-C-reactive protein; P-Creatinine, plasma-Creatinine. Data are given as mean (SD) or median (range). aPatients analyzed 0–6 months in group N, n = 19; group B, n = 25; group C, n = 24. bPatients analyzed 0–12 months in group N, n = 18; group B, n = 25; Group C; n = 23. cPatients analyzed 0–6 months in group N, n = 20; group B, n = 25; group C, n = 25. dPatients analyzed 0–12 months in group N, n = 18; group B, n = 25; group C, n = 21